ERBB2 and breast cancer: This study found that ZA as an adjunct to neoadjuvant chemotherapy had no beneficial effect in patients with stage II/III HER2-negative breast cancer receiving TAC chemotherapy and, in pre- and postmenopausal patients, was associated with worse OS, but not DFS.